Related references
Note: Only part of the references are listed.The effect of hypoxia on PD-L1 expression in bladder cancer
Vicky Smith et al.
BMC CANCER (2021)
The role of hypoxia-inducible factor 1 in tumor immune evasion
Li You et al.
MEDICINAL RESEARCH REVIEWS (2021)
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Wei Mu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
18F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment
Jie Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
Maria Togo et al.
BRITISH JOURNAL OF CANCER (2020)
18F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer
Li Li et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response
Li Li et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer
Yan Xing et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer
Fabio Grizzi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
Chuling Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
F-18-alfatide positron emission tomography may predict anti-angiogenic responses
Jie Liu et al.
ONCOLOGY REPORTS (2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
A. N. Niemeijer et al.
NATURE COMMUNICATIONS (2018)
High FDG uptake on PET is associated with negative cell-to-cell adhesion molecule E-cadherin expression in lung adenocarcinoma
Kotaro Higashi et al.
ANNALS OF NUCLEAR MEDICINE (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
Yih-Leong Chang et al.
EUROPEAN JOURNAL OF CANCER (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT
Jianhong Zuo et al.
MEDICAL ONCOLOGY (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients
Song Gao et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3
Yu-Ping Yu et al.
BIOMATERIALS (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma
Yongli Shi et al.
DIAGNOSTIC PATHOLOGY (2013)
First Experience of 18F-Alfatide in Lung Cancer Patients Using a New Lyophilized Kit for Rapid Radiofluorination
Weixing Wan et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Fabienne Danhier et al.
MOLECULAR PHARMACEUTICS (2012)
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Kornelia Polyak et al.
NATURE REVIEWS CANCER (2009)
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man
Ambros J. Beer et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
